23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 Abril 2024 - 5:05PM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company, will present data on its
two clinical stage programs, 23ME-01473 targeting ULBP6, and
23ME-00610 targeting CD200R1, at the American Association for
Cancer Research (AACR) Annual Meeting 2024, taking place in San
Diego, CA, April 5-10, 2024.
23ME-001473 (‘1473) - Clinical-Stage
Dual Mechanism Monoclonal Antibody Targeting ULBP6
Key takeaways:
- 23andMe used its proprietary database of human genetic and
health information to discover germline variants of ULBP6
associated with higher risks of immune disease and lower risks of
cancer, suggesting the potential of ULBP6 as a novel
immuno-oncology (I/O) drug target.
- Data also show soluble ULBP6 is a dominant immunosuppressor
compared to other soluble NKG2D ligands due to its highest binding
affinity to NKG2D among all NKG2D ligands.
- ‘1473 is a high affinity, Fc effector-enhanced, anti-ULBP6
antibody that restores the activation and tumor cell killing
capacity of natural killer (NK) and T cells through the dual
mechanisms of NKG2D and FcγRIIIa activation.
Key details:
- ULBP6 is a stress-induced ligand that is upregulated on the
surface of cancer cells and binds to the activating immunoreceptor
NKG2D found on NK and T cells.
- ULBP6 can be shed from the cell surface of tumor cells into a
soluble form that acts as an immunosuppressive decoy to evade
immune surveillance. Soluble ULBP6 is elevated in cancer patient
plasma.
- Of all human NKG2D ligands, ULBP6 exhibits the highest binding
affinity to NKG2D, which correlates with the high potency of
soluble ULBP6 in suppressing PBMC-mediated interferon-gamma
secretion and promoting tumor cell growth in vitro.
- Expression profiling of ULBP6 in various tumors using The
Cancer Genome Atlas and immunohistochemistry reveals its elevated
expression in squamous cell carcinomas and a subset of
adenocarcinomas.
- ‘1473’s dual synergistic activation of NKG2D and FcγRIIIa leads
to optimal activation of NK cells, which may reverse immune
suppression and circumvent resistance to immune-checkpoint
inhibitors due to the loss of neoantigen presentation in
tumors.
- ‘1473 is currently being evaluated in a Phase I clinical trial
for patients with advanced solid tumors (NCT06290388).
23ME-00610 - Clinical-Stage Monoclonal
Antibody Targeting CD200R1
Key Takeaways:
- CD200R1 is a dominant immune checkpoint and differentiated from
PD-1, based on both the pattern of expression on tumor infiltrating
immune cells from patient tumors and the pattern of activation on
patient peripheral mononuclear blood cells.
- 23andMe preclinical results support the potential for
23ME-00610 to combine with anti-PD-1 and antiangiogenics.
Key Details:
- Prevalence of CD200R1 and its ligand CD200 was characterized on
tumor samples from patients with clear cell renal cell and serous
ovarian carcinomas.
- CD200R1 is broadly expressed on tumor-infiltrating immune
cells, including T cells and NK cells, whereas expression of PD-1
is predominantly restricted to T cells.
- 23ME-00610 differentially enhanced interferon-gamma secretion
from cancer patient peripheral blood mononuclear cells relative to
anti-PD-1, and 23ME-00610 enhanced both T and NK cell anti-tumor
activity.
- CD200/R1 is an independent immunosuppressive pathway from
PD/L-1, with potential for synergism in patients with cancer based
on preclinical combination data with primary human T cells.
- CD200, the ligand of CD200R1, is expressed on both tumor cells
and endothelial cells, and combination anti-CD200 with anti-VEGF
led to tumor growth inhibition relative to single agents in a
preclinical mouse model.
- 23ME-00610 is currently in the Phase 2a portion of a Phase 1/2a
clinical trial (NCT05199272).
The presentations will be available on the 23andMe Investor
Relations and Therapeutics websites on April 8, 2024.
Presentation details - 23ME-01473:
Oral presentation
- Title: Discovery of ULBP6 as a novel
immuno-oncology target using pleiotropic signals from 23andMeʼs
genetic and health survey database
- Session Type: Minisymposium
- Session Category: Experimental and Molecular
Therapeutics
- Session Title: Drug Discovery 1: New Targets
and Approaches
- Session Date and Time: Monday, April 8, 2024,
3:20-3:35 PM PT
- Location: Room 30, Upper Level of the San
Diego Convention Center
- Published Abstract Number: 3903
Poster presentation
- Title: 23ME-01473, a novel anti-ULBP6/2/5
monoclonal antibody, reinvigorates anti-tumor NK cell function
through NKG2D and FcγRIIIa activation
- Session Category: Clinical Research
- Session Title: Antibodies 1
- Session Date and Time: Monday, April 8, 2024,
9:00 AM - 12:30 PM PT
- Location: Poster Section 38
- Poster Board Number: 21
- Published Abstract Number: 2375
Presentation Details: 23ME-00610:
Poster presentation
- Title: New insights into targeting the CD200R1
pathway in T and NK cells using 23ME-00610 as a single agent or in
combination
- Session Category: Clinical Research
- Session Title: Antibodies 1
- Session Date and Time: Monday, April 8, 2024,
9:00 AM - 12:30 PM PT
- Location: Poster Section 38
- Poster Board Number: 5
- Published Abstract Number: 2359
About 23andMe23andMe is a genetics-led consumer
healthcare and biopharmaceutical company empowering a healthier
future. For more information, please visit www.23andMe.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding its future clinical trials and
plans of 23andMe’s therapeutics business. All statements, other
than statements of historical fact, included or incorporated in
this press release, including statements regarding 23andMe’s
strategy, the plans for and results of its clinical trials and
objectives of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," “predicts,” "continue," "will," “schedule,” and "would"
or, in each case, their negative or other variations or comparable
terminology, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are predictions
based on 23andMe’s current expectations and projections about
future events and various assumptions. 23andMe cannot guarantee
that it will actually achieve the plans, intentions, or
expectations disclosed in its forward-looking statements and you
should not place undue reliance on 23andMe’s forward-looking
statements. These forward-looking statements involve a number of
risks, uncertainties (many of which are beyond the control of
23andMe), or other assumptions that may cause actual results or
performance to differ materially from those expressed or implied by
these forward-looking statements. The forward-looking statements
contained herein are also subject generally to other risks and
uncertainties that are described from time to time in the Company’s
filings with the Securities and Exchange Commission, including
under Item 1A, “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K, as filed with the Securities and Exchange
Commission, and as revised and updated by our Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K. The statements made
herein are made as of the date of this press release and, except as
may be required by law, 23andMe undertakes no obligation to update
them, whether as a result of new information, developments, or
otherwise.
Contacts: Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
23andMe (NASDAQ:ME)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024